Epigenetic biomarker znf545 for diagnosing and prognosis of gastric cancer
AssigneeThe Chinese University of Hong Kong
InventorsJUN YU, Joseph Jao Yiu Sung
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ZNF545 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ZNF545 gene expression or activity
Claims24
A method for detecting gastric cancer in a subject, comprising the steps of:
- (a) measuring expression level of ZNF545 in a sample taken from the subject, and
- (b) comparing the expression level obtained in step (a) with a standard control,
- wherein a decrease in the expression level of ZNF545 when compared with the standard control indicates the subject having gastric cancer.
-16. (canceled)
A method for detecting gastric cancer in a subject, comprising the steps of:
- (a) treating a sample taken from the subject with an agent that differentially modifies methylated and unmethylated DNA;
- and
- (b) determining whether each CpG in a CpG-containing genomic sequence is methylated or unmethylated, wherein the CpG-containing genomic sequence is at least a segment of SEQ ID NO:1 or 2 and comprising at least one CpG,
- wherein presence of one methylated CpG in the CpG-containing genomic sequence indicates the subject having gastric cancer.
-36. (canceled)
A kit for detecting gastric cancer in a subject, comprising (1) a standard control that provides an average amount of ZNF545 protein or ZNF545 mRNA found in non-cancerous gastric tissue;
- and (2) an agent that specifically and quantitatively identifies ZNF545 protein or ZNF545 mRNA.
-44. (canceled)
A method for inhibiting growth of a gastric cancer cell, comprising contacting the gastric cancer cell with an effective amount of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:5 or a nucleic acid comprising a polynucleotide sequence encoding SEQ ID NO:5.
An isolated nucleic acid having the nucleotide sequence at least 95% identical to a segment of about 20-100 contiguous nucleotides of SEQ ID NO:1-4, 6, 7, 12-16, or 17 or complement thereof.
-52. (canceled)
Dependencies are inferred from the claim text.